恒瑞医药：海曲泊帕乙醇胺片药品上市许可申请获受理

蓝鲸财经2025-08-12

蓝鲸新闻8月12日电，恒瑞医药(600276.SH)公告称，公司收到国家药监局下发的《受理通知书》，海曲泊帕乙醇胺片的药品上市许可申请获国家药监局受理，适应症为适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的持续性及慢性原发免疫性血小板减少症（ITP）成人及≥6岁的儿童患者。该药品Ⅲ期临床试验已达到预设的主要研究终点，且长期治疗的安全性、有效性良好。海曲泊帕乙醇胺片已获批上市两个适应症，包括慢性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2558961744?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-12 16:39","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2558961744","market":"hk","top_or_hot":-1,"title":"恒瑞医药：海曲泊帕乙醇胺片药品上市许可申请获受理","media":"蓝鲸财经","content":"<div>\n<p>蓝鲸新闻8月12日电，恒瑞医药(600276.SH)公告称，公司收到国家药监局下发的《受理通知书》，海曲泊帕乙醇胺片的药品上市许可申请获国家药监局受理，适应症为适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的持续性及慢性原发免疫性血小板减少症（ITP）成人及≥6岁的儿童患者。该药品Ⅲ期临床试验已达到预设的主要研究终点，且长期治疗的安全性、有效性良好。海曲泊帕乙醇胺片已获批上市两个适应症，包括慢性...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081216412697429f52&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药：海曲泊帕乙醇胺片药品上市许可申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药：海曲泊帕乙醇胺片药品上市许可申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-12 16:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081216412697429f52&s=b><strong>蓝鲸财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>蓝鲸新闻8月12日电，恒瑞医药(600276.SH)公告称，公司收到国家药监局下发的《受理通知书》，海曲泊帕乙醇胺片的药品上市许可申请获国家药监局受理，适应症为适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的持续性及慢性原发免疫性血小板减少症（ITP）成人及≥6岁的儿童患者。该药品Ⅲ期临床试验已达到预设的主要研究终点，且长期治疗的安全性、有效性良好。海曲泊帕乙醇胺片已获批上市两个适应症，包括慢性...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081216412697429f52&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081216412697429f52&s=b","article_id":"2558961744","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081216412697429f52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2558961744","pubTimestamp":1754987994,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"蓝鲸新闻8月12日电，恒瑞医药(600276.SH)公告称，公司收到国家药监局下发的《受理通知书》，海曲泊帕乙醇胺片的药品上市许可申请获国家药监局受理，适应症为适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的持续性及慢性原发免疫性血小板减少症（ITP）成人及≥6岁的儿童患者。该药品Ⅲ期临床试验已达到预设的主要研究终点，且长期治疗的安全性、有效性良好。海曲泊帕乙醇胺片已获批上市两个适应症，包括慢性原发免疫性血小板减少症成人患者的治疗和重型再生障碍性贫血成人患者的治疗。截至目前，相关项目累计研发投入约4.46亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01276":"恒瑞医药","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK1191":"制药"},"translate_title":"Hengrui Medicine: The application for marketing authorization of Hetrombopag Ethanolamine Tablets was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"蓝鲸新闻8月12日电，恒瑞医药(600276.SH)公告称，公司收到国家药监局下发的《受理通知书》，海曲泊帕乙醇胺片的药品上市许可申请获国家药监局受理，适应症为适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的持续性及慢性原发免疫性血小板减少症（ITP）成人及≥6岁的儿童患者。该药品Ⅲ期临床试验已达到预设的主要研究终点，且长期治疗的安全性、有效性良好。海曲泊帕乙醇胺片已获批上市两个适应症，包括慢性原发免疫性血小板减少症成人患者的治疗和重型再生障碍性贫血成人患者的治疗。截至目前，相关项目累计研发投入约4.46亿元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2558961744","isCrawlerRequest":true}